Under the terms of the agreement Boehringer receives global rights to the asset, excluding greater China. Simcere is eligible to receive an upfront payment as well as success-based development, ...

There's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape, a process that can go haywire or fail to work. But what if the body could ...

Boehringer Ingelheim and Simcere are developing SIM0709, a pre-clinical bispecific antibody, for treating inflammatory bowel disease (IBD).

Immune signaling in IBD triggers tumor-promoting neutrophils which is linked to an increased risk of colorectal cancer.